Potential deal could create one of the world’s largest pharmaceutical companies
AstraZeneca has reportedly explored a potential merger with Bristol Myers Squibb in a deal that could create a pharmaceutical giant valued at nearly $400 billion.
According to reports, including sources first cited by the Financial Times, the two companies have held early-stage discussions about a possible combination in recent months. However, it remains unclear whether talks are still active or if an agreement will ultimately be reached.
A merger between the two companies would bring together AstraZeneca’s strong global presence with Bristol Myers Squibb’s established position in the United States, creating one of the largest pharmaceutical companies in the world.
A larger US presence for AstraZeneca
Bristol Myers Squibb currently has a market value of around $133 billion and would provide AstraZeneca with a stronger foothold in the US pharmaceutical market, which is considered essential to the UK-based company’s long-term growth strategy.
AstraZeneca has a market capitalization of approximately £196 billion ($265 billion) and recently began listing its shares directly on the New York Stock Exchange.
The move followed reports that CEO Pascal Soriot was considering shifting the company’s primary listing to the US due to concerns about the UK business environment. However, AstraZeneca has said the NYSE listing is part of a broader strategy to double revenue by 2030, with half of that growth expected to come from the US market.
AstraZeneca investors may question the deal
Some analysts believe AstraZeneca shareholders may have concerns about a potential acquisition of Bristol Myers Squibb.
Mizuho analyst Jared Holz noted that AstraZeneca’s earnings per share are expected to grow by more than 10% annually over the next five years, while Bristol Myers Squibb’s earnings per share could decline during the same period.
“Investors will argue that AstraZeneca does not need Bristol Myers,” Holz said, adding that the merger would be difficult to justify unless significant cost savings or business synergies could offset potential declines in revenue and earnings.
However, Holz also suggested that the current regulatory environment could make a large pharmaceutical deal more achievable, pointing to what he described as a relatively favorable stance toward mergers from the Trump administration.
Potential regulatory and competition concerns
The two companies already compete in several areas of oncology, particularly through their checkpoint inhibitor treatments.
Bristol Myers Squibb’s Opdivo (nivolumab) and AstraZeneca’s Imfinzi (durvalumab) are both used in cancer treatments, including lung cancer and other solid tumors.
BMO Capital Markets said the significant overlap between the companies’ businesses could complicate a potential merger and increase the likelihood of regulatory scrutiny over competition concerns.
AstraZeneca has faced takeover interest before
The reported discussions with Bristol Myers Squibb come more than a decade after AstraZeneca successfully resisted a major takeover attempt from Pfizer.
In 2014, AstraZeneca rejected Pfizer’s final acquisition proposal, which valued the company at around £69 billion ($93 billion).
